Home › High Blood Pressure in Pregnancy › NCT06220721
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
Recruiting
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Postpartum day 0-4 * Age ≥ 18 years * Able to communicate in English or in Spanish * Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records. Exclusion Criteria: * Pre-gestational hypertension * Type 1 or type 2 diabetes mellitus * Admitted to intensive care unit at the time of screening * Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization * Getting discharged on the day of screening * Known allergy or contraindication to nifedipine ER * Inability or unwillingness to provide informed consent * Already taking long-acting antihypertensive medication for standard care * Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus
About the study
The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.
What is being tested
- Nifedipine ER (drug)
Sponsor: Medical College of Wisconsin · Participants: 618 · Started: Oct 23, 2024
Contact the study team
- Alyssa M Hernandez, DO · Phone: 4148055285
- Amandla Stanley, MSN · Phone: 4148056691
Official record on ClinicalTrials.gov — NCT06220721
Locations in the U.S.
| Illinois | Northwestern University, Chicago |
| Wisconsin | Medical College of Wisconsin, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.